Logo

Transgenomic Extends Supply Agreement with Geron for Nucleic Acid Building Blocks

Apr 20, 2005

NEW YORK, April 20 (GenomeWeb News) - Transgenomic will supply Geron with additional modified nucleic acid reagents to synthesize an anti-cancer drug, the Omaha, Neb.-based company said today.

 

The additional shipments, which add to an existing supply agreement between the two companies, will be completed later this year.

 

Geron's cancer drug is a thio-phosporamidate oligonucleotide, for which Transgenomic provides the building blocks.

Breaking News
The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.